Thursday, 6 October 2022

BioLargo Secures Product Recovery Management (PRM) as Channel Partner and Contract Manufacturer for BioLargo’s Water Treatment Technologies

Westminster, CA – October 6, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it signed a channel partnership agreement with Product Recovery Management, Inc. to sell and distribute BioLargo’s water treatment systems and act as a contract manufacturer.

Product Recovery Management (PRM) (https://www.prmfiltration.com/), based out of Butner, NC, is a UL-certified equipment integrator specializing in remediation services with over 40 years of history serving customers. PRM designs and manufactures treatment systems that address a wide variety of contamination challenges in the remediation and landfill industries, including PFAS contamination. Their Butner operations include a 250,000 square foot manufacturing facility with large-scale fabrication capabilities.

The channel partner agreement grants PRM a license to sell and distribute BioLargo’s innovative water and wastewater treatment technologies, including but not limited to the Aqueous Electrostatic Concentrator (AEC), BioLargo’s effective, affordable, low-waste solution for removing per- and polyfluoroalkyl substances (PFAS) from water. PRM will also be authorized to sell BioLargo’s Advanced Oxidation System (AOS) technology, the energy-efficient and affordable solution for simultaneous water disinfection and micropollutant treatment.

PRM will also be a contract manufacturer for BioLargo’s water treatment technologies, including the AEC, the AOS, as well as other treatment systems designed by BioLargo (e.g., reverse osmosis systems).

“PRM has substantial expertise and infrastructure to support the roll-out and manufacturing of our cleantech systems. This relationship will allow us to more readily meet the growing demand for our systems and expand our reach into the market. We have already begun scoping our first project together,” says Randall Moore, President of BioLargo Engineering, Science & Technologies (BioLargo’s engineering subsidiary – www.BioLargoEngineering.com).

“BioLargo’s AEC and AOS technologies are unique and valuable tools for targeted removal of tough-to-treat water contaminants including PFAS and micropollutants, both of which currently lack effective and affordable options in the marketplace. We recognized in BioLargo a commitment to serve customers with technical excellence and reliable results. We look forward to working with the BioLargo team,” said Robert Phillips, Jr., President of Product Recovery Management.

 

About PRM:

Headquartered in Butner, NC. PRM was founded in 1990 by Mel and Brian Phillips. Originating as Phillips Electric Company in 1976, PRM is now a premier environmental remediation and landfill gas company with systems operating across the globe. PRM is an Original Equipment Manufacturer (OEM) of pollution control and other equipment, mainly focused on the Remediation and Landfill Industries. Their experiences and talents are well diversified.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 28 September 2022

BioLargo Launches New Website To Highlight PFAS Mitigation Solutions

Source - Water Online: https://www.wateronline.com/doc/biolargo-launches-new-website-to-highlight-pfas-mitigation-solutions-0001 


BioLargo, Inc., developer of innovative cleantech technologies that target tough water and air contamination challenges, has launched a new website to promote its line of systems and services that tackle water contaminated by per- and polyfluoroalkyl substances (PFAS). The company also announced that it will be available to discuss its PFAS mitigation tools with prospective customers and distributors at the upcoming WEFTEC conference and trade show in New Orleans from October 8-12, 2022.

PFAS are an expansive class of man-made chemicals that contaminate thousands of drinking water sources around the US, with links to numerous negative health effects including cancer, hormone dysfunction, developmental disorders, and more. Due to their extremely stable chemical structure, PFAS do not break down naturally in the environment or in humans, causing them to bioaccumulate and inflict health impacts slowly over time. Another consequence of their stability is that there are few effective tools for removing them from water and wastewater.

BioLargo developed its own treatment technology to remove PFAS from water and started the commercialization process last October. Its system, called the Aqueous Electrostatic Concentrator (AEC), works by separating PFAS compounds in an electric field and depositing them onto proprietary membranes. It has been proven to remove a wide number of PFAS compounds to below the level of detection, consuming as little as 30 cents per 1,000 gallons in electricity costs. Crucially, the AEC generates as little as 1/1000 the PFAS-laden solid waste compared to other treatment options like carbon filtration and ion exchange, making it a low-carbon treatment option for eco-conscious treatment operations.

BioLargo’s new website, https://www.bestpfastreatment.com/, highlights the AEC and BioLargo’s other PFAS mitigation solutions, including its PFAS testing program (a way to quickly and affordably determine a site’s PFAS contamination levels and appropriate treatment solutions). It also offers insights into its broader environmental engineering and system integration services.

The website aims to become an educational resource for industry users by hosting educational articles on PFAS contamination, which is an ever-evolving issue with complex regulatory and techno-economic considerations that shift nearly every week.

“Our goal is to become a resource for those facing PFAS issues,” says Tonya Chandler, Director of Commercialization for BioLargo, Inc. “The landscape of PFAS regulations and mitigation technologies changes day by day. We wanted to offer a place where the industry could learn more about PFAS and how to remove it.”

BioLargo staff will be attending WEFTEC, the foremost water and wastewater sector conference and trade show in New Orleans from October 8-12, 2022. They will be available to discuss PFAS, the AEC and the company’s other solutions . Interested parties in attendance are encouraged to reach out to BioLargo to arrange meetings using the following contact information:

Tonya Chandler, Director of Commercialization
Email: Tonya.chandler@biolargo.com
Phone: +1-608-397-8301

Friday, 19 August 2022

BioLargo sees 'a major opportunity' for PFAS unit as it reports a surge in second-quarter revenue

Source: Proactive Investors (https://www.proactiveinvestors.ca/companies/news/990601/biolargo-sees-a-major-opportunity-for-pfas-unit-as-it-reports-a-surge-in-second-quarter-revenue-990601.html


BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert takes Proactive's Stephen Gunnion through the company's second-quarter results, which show a 185% year-over-year jump in revenue to $1.32 million on the back of strong contributions from its engineering and environmental divisions.

Calvert telling Proactive that the company's PFAS (per- and polyfluoroalkyl substances) business is a major opportunity, and BioLargo is at the forefront of real environmental impact, working with channel partners to solve some of today’s toughest environmental challenges.

Tuesday, 16 August 2022

BioLargo Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Published in Quarterly Report

Quarterly Report highlighted by profitable operating subsidiaries, growth of white-label odor product sales, and large engineering projects

Westminster, CA – August 16, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the period ended June 30, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the quarterly report and a discussion of key business initiatives with the most potential to stimulate growth.

The company will hold an investor webcast on Wednesday, August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/46358

BioLargo’s President and CEO Dennis P. Calvert said, “We are proud of the entire BioLargo team working together and executing on all fronts as we continue growing the business through bigger and better projects. It has been incredible to watch our team land and expand into new client projects through great service and deliverables. PFAS is a major opportunity for us, and we are on the forefront of real environmental impact, working with channel partners to solve some of today’s toughest environmental challenges.”

Financial highlights

  • Company-wide consolidated revenue for the three and six months ended June 30, 2022, was $1,323,000 and $2,287,000, which is a 185% and 121% increase over the same periods in 2021; revenue this quarter was a 37% increase compared with the first quarter of 2022.
  • Revenues from ONM Environmental, the company’s odor and VOC control subsidiary, for the three and six months ended June 30, 2022, were $700,000 and $1,300,000, an increase of $344,000 and $658,000, from the same periods in 2021. In the second quarter of 2022, this subsidiary generated a net operating income of $11,000, compared to a net operating loss of $107,000 in the same period of 2021.
  • Revenues from third parties for BioLargo Engineering, Science & Technologies, the company’s environmental engineering subsidiary, for the three and six months ended June 30, 2022, were $617,000 and $972,000, an increase of $434,000 and $698,000, from the same periods in 2021. In the second quarter of 2022, this subsidiary generated a net operating income of $56,000, compared to a net operating loss of $190,000 in the same period of 2021.

Commercial and developmental highlights

  • First PFAS customer – the company recently secured its first PFAS customer. As part of this project, BioLargo will engineer a comprehensive PFAS mitigation plan for an industrial site, and has signed an agreement with a new channel partner to sell the company’s PFAS treatment equipment and engineering services.
  • Ikigai’s POOPH – The company’s white-label pet odor control product partnership with Ikigai is advancing well and generating increasing revenues both from manufacturing the product and from license royalties. Sales thus far have exceeded early expectations, and the company’s partners at Ikigai are confident that growth will continue, especially as they push to get the product onto shelves at major retailers.
  • Garratt-Callahan partnership – The company expects first sales of the “minimal liquid discharge” (MLD) wastewater treatment equipment developed in partnership with Garratt-Callahan to begin soon, following discussions with an expanding list of Garratt-Callahan customers.
  • Larger engineering projects – In this quarter, BioLargo Engineering, Science & Technologies executed engineering projects for new customers, including its project to develop prototypes with Ultra Safe Nuclear, and the waste-to-energy plant project in South America. With both of these projects, early phase work is nearly done, and management anticipates that additional phases will soon begin, with the scope of work and level of engagement expanding.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Friday, 12 August 2022

BioLargo Q2 2022 Earnings Results Webcast and Conference Call on Wednesday, August 17, 2022 - 4 PM Eastern Time

Westminster, CA – August 12, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company announced it will host an investor webcast and conference call on Wednesday August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three and six months ended June 30, 2022, discuss recent milestones and ongoing business initiatives, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/46358

Teleconference Domestic:

888-506-0062

Teleconference International:

Participant Access Code:

973-528-0011

656092

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Thursday, August 17, 2023

Teleconference Replay Expiration:

Wednesday, August 31, 2022

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

46358

 

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

 

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 11 August 2022

BioLargo Secures First PFAS Mitigation Customer and Signs New Channel Partner for PFAS Remediation

Westminster, CA – August 11, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has secured its first customer to engineer a comprehensive PFAS mitigation plan for an industrial site, and has signed an agreement with a new channel partner to sell the company’s PFAS treatment equipment and engineering services.

Per- and polyfluoroalkyl substances (PFAS) are man-made persistent, bioaccumulative chemicals linked to widespread negative health effects including cancer, birth defects, and more. They are known to contaminate surface and groundwater in all 50 states, affecting multiple industries. Through its environmental engineering subsidiary BioLargo Engineering, Science & Technologies, BioLargo offers PFAS mitigation services including field testing, engineering design, system installation, operation, and maintenance, as well as water treatment systems including the company’s own proprietary PFAS treatment technology the Aqueous Electrostatic Concentrator (AEC).

The customer contract is for the first phase of what is expected to be a multi-phase comprehensive PFAS remediation project. The contract was secured in collaboration with a new channel partner, which has been appointed to promote, market, and distribute BioLargo’s water treatment equipment and PFAS-related engineering and project integration services.

BioLargo’s President and CEO Dennis P. Calvert said, “Securing our first customer is obviously a very important step for BioLargo as a comprehensive solutions-provider in the PFAS remediation market. We will look forward to sharing more information about this project as well as our other activities with channel partners in the PFAS mitigation space.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 4 August 2022

Proactive Investors Interview: BioLargo says it will report record quarterly revenue, with more record quarters to follow

Source: Proactive Investors (https://www.proactiveinvestors.ca/companies/news/989295/biolargo-says-it-will-report-record-quarterly-revenue-with-more-record-quarters-to-follow-989295.html 

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert says a 37% quarter-over-quarter increase in second-quarter revenue to around $1.3 million is "the culmination of a lot of work".

"It really is the moment in which we are seeing some pretty dramatic percentage increases," Calvert told Proactive.

In part, Calvert attributed the quarterly gains to expanded sales of pet control products and wastewater treatment technologies.

"The number are getting more and more ... meaningful," he added. "Two of our operating units we reported on last quarter were teetering on profitability. We're pretty sure we've now achieved that objective."